Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs

JAMA Intern Med. 2021 Nov 1;181(11):1521-1522. doi: 10.1001/jamainternmed.2021.3505.

Abstract

This cross-sectional study examines how information on overall survival benefits of novel cancer drug indications is communicated in labeling.

MeSH terms

  • Access to Information
  • Antineoplastic Agents / pharmacology*
  • Data Display*
  • Drug Approval / methods
  • Drug Labeling* / methods
  • Drug Labeling* / standards
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / mortality
  • Research Design / standards*
  • Survival Analysis
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents